A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, J.Y.[Lee, J.Y.] | - |
dc.contributor.author | Kim, J.W.[Kim, J.W.] | - |
dc.contributor.author | Lim, M.C.[Lim, M.C.] | - |
dc.contributor.author | Kim, S.[Kim, S.] | - |
dc.contributor.author | Kim, H.S.[Kim, H.S.] | - |
dc.contributor.author | Choi, C.H.[Choi, C.H.] | - |
dc.contributor.author | Yi, J.Y.[Yi, J.Y.] | - |
dc.contributor.author | Park, S.Y.[Park, S.Y.] | - |
dc.contributor.author | Kim, B.G.[Kim, B.G.] | - |
dc.date.accessioned | 2021-07-29T02:25:42Z | - |
dc.date.available | 2021-07-29T02:25:42Z | - |
dc.date.created | 2020-07-13 | - |
dc.date.issued | 2019-11 | - |
dc.identifier.issn | 2005-0399 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/14074 | - |
dc.description.abstract | BACKGROUND: A single-arm phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in the treatment of advanced-stage ovarian cancer has begun in Korea. We hypothesized that adding durvalumab (anti-programmed death-ligand 1 antibody) and tremelimumab (anti-cytotoxic T-lymphocyte-associated protein 4 antibody) to chemotherapy in treating this cancer can increase progression-free survival (PFS) with minimal effects on safety. METHODS: During treatment, serial biopsies will be performed on pre-treatment, at interval debulking surgery and progression to identify immune biomarkers and changes in the tumor microenvironment. Patients with histologically confirmed stage IIIC/IV epithelial ovarian cancer are offered durvalumab, tremelimumab plus chemotherapy for neoadjuvant chemotherapy and durvalumab plus chemotherapy for adjuvant chemotherapy. Twenty-four patients will be included from four Korean institutions within 1 year. The primary endpoint is a 12-month PFS rate. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03899610. Copyright © 2019. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NLM (Medline) | - |
dc.title | A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, C.H.[Choi, C.H.] | - |
dc.contributor.affiliatedAuthor | Kim, B.G.[Kim, B.G.] | - |
dc.identifier.doi | 10.3802/jgo.2019.30.e112 | - |
dc.identifier.scopusid | 2-s2.0-85072847844 | - |
dc.identifier.wosid | 000488608300015 | - |
dc.identifier.bibliographicCitation | Journal of gynecologic oncology, v.30, no.6, pp.e112 | - |
dc.relation.isPartOf | Journal of gynecologic oncology | - |
dc.citation.title | Journal of gynecologic oncology | - |
dc.citation.volume | 30 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | e112 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002521351 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Obstetrics & Gynecology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Obstetrics & Gynecology | - |
dc.subject.keywordPlus | PRIMARY SURGERY | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Durvalumab | - |
dc.subject.keywordAuthor | Epithelial Ovarian Cancer | - |
dc.subject.keywordAuthor | Immunotherapy | - |
dc.subject.keywordAuthor | Tremelimumab | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.